Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

3yrs ago Private Equity privateequitywire Views: 368

BTIG Healthcare adds MD to investment banking team

Submitted 07/08/2020 - 9:58am

BTIG has appointed J Rory Rohan as a Managing Director within its Healthcare Investment Banking division. Rohan will be based in the firm’s New York office, and will report to KC Stone, Managing Director and Head of Healthcare Investment Banking, at BTIG.

In his new role, Rohan will work to expand the firm’s life sciences capabilities and private placement services across its investment banking verticals. As a dedicated product specialist, he will be tasked with structuring and originating transactions for corporate clients. BTIG Investment Banking has seen a steady increase in its deal flow and banking activity in the last 12 months. To support the needs of its growing corporate client segment, the firm has hired a number of senior bankers this year.

“We are pleased to welcome Rory to BTIG,” says Matt Clark, Chief Operating Officer, BTIG Investment Banking. “Life sciences is an important area of growth for the firm and we believe Rory’s experience will make an immediate impact on clients as they evaluate the marketplace. As a private placement specialist, he will also operate as a valuable extension of our Equity Capital Markets team, where he can help clients strategise capital raising solutions.”

Prior to BTIG, Rohan was a Managing Director at RHK Capital, focused on private offerings of debt and equity for middle-market issuers. He has more than 15 years of transactional experience. Earlier in his career, Rohan held several similar private capital markets roles at Enclave Capital and Midtown Partners & Co. He co-authored “Monetary Reform from a Comparative-Theoretical Perspective,” which appears in the Fall 2004 edition of the Quarterly Journal of Austrian Economics. Rohan earned a BS in economics from Hampden-Sydney College, and an MBA from New York University Stern School of Business.

“Given Rory’s life science expertise, we are confident that he will strengthen our healthcare banking platform and enhance our ability to assist clients at all stages of development,” says Stone. “Partnering with our existing team, he will help lead important discussions with key prospects, and provide meaningful guidance to clients throughout the offering process.”

Tags Moves & Appointments

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.